
浏览全部资源
扫码关注微信
纸质出版:2012
移动端阅览
林国太,李昌桂,张益明,邹智聪,刘英发,林元田,吴银锁.浅表性膀胱癌经尿道电切术后复发的原因及预防策略[J].陆军军医大学学报(原第三军医大学学报),2012,34(18):1884-1887.
Lin Guotai,Li Changgui,Zhang Yiming,Zou Zhicong,Liu Yingfa,Lin Yuantian,Wu Yinsuo.Reasons and preventive strategies of post-TUR neoplasm recurrences for superficial transitional cell carcinoma[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(18):1884-1887.
林国太,李昌桂,张益明,邹智聪,刘英发,林元田,吴银锁.浅表性膀胱癌经尿道电切术后复发的原因及预防策略[J].陆军军医大学学报(原第三军医大学学报),2012,34(18):1884-1887. DOI:
Lin Guotai,Li Changgui,Zhang Yiming,Zou Zhicong,Liu Yingfa,Lin Yuantian,Wu Yinsuo.Reasons and preventive strategies of post-TUR neoplasm recurrences for superficial transitional cell carcinoma[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(18):1884-1887. DOI:
目的 探讨浅表性膀胱癌(superficial transitional cell carcinoma,STCC)经尿道膀胱肿瘤电切术(transurethral resection of bladder tumor
TURBt)后复发的原因及预防策略。 方法 随机选取我院2001年1月至2007年6月收治的128例STCC患者(对照组)行TURBt术后丝裂霉素C膀胱灌注化疗,另取2007年7月至2011年12月81例STCC患者(观察组)行TURBt术后丝裂霉素C+干扰素联合膀胱灌注化疗,回顾性分析其肿瘤复发情况、化疗方案、手术操作规范等,结合文献探讨其术后复发的原因及预防措施。 结果 209例患者术后获随访(31±3)个月,总复发率28.23%,12例术后病理分期分级进展。观察组肿瘤复发率为14.15%,对照组为36.72%;单发肿瘤复发率为23.23%,多发为42.59%;T
a
期6.25%,T
1
期34.78%;G
1
级17.05%、G
2
级37.25%、G
3
级62.07%。观察组获得肿瘤分期、分级、数目等情况与对照组无明显差异(P0.05),但观察组肿瘤复发率较对照组低(P0.01);单发、T
a
期、低级别的肿瘤的复发率分别较多发、T
1
期、高级别的肿瘤低(P0.01)。 结论 STCC经尿道电切术后复发主要原因是肿瘤高分级及高分期,肿瘤多发性及非乳头状,肿瘤基底电切深度及范围不够,肿瘤周围存在肉眼难以发觉的隐性卫星病灶及人为因素遗漏小肿瘤,膀胱内残留肿瘤组织碎片种植,灌注化疗失败等。规范化彻底性切除肿瘤原发病灶,术后即刻开始联合应用化学药物及免疫生物制剂规范化膀胱灌注化疗,可提高临床疗效,降低复发率。
Objective To analyze the reason and preventive strategies of neoplasm recurrences after transurethral resection (TUR) for patients with superficial transitional cell carcinoma (STCC). Methods From Jan. 2001 to Jun. 2007
128 randomly STCC patients who had undergone TUR in our hospital and received vesical irrigative chemotherapy merely with Mutamycin C after surgery
were assigned as the control group. Another series of 81 STCC patients in our hospital from July 2007 to Dec 2011 were selected as the observation group
and these patients received vesical irrigative chemotherapy with mutamycin C
as well as interferon after TUR. Of all patients
clinical data such as neoplasm recurrence
chemotherapy schemes and operative procedures
etc. was analyzed and summarized. Subsequently
a discussion on high risks of postoperative recurrences and the preventive measures was made combined with the latest literatures. Results A total of 209 patients were followed up for an average time of 31±3 months
with a total recurrence rate of 28.23%. Twelve patients accepted reoperation and presented a progression in clinicopathologic stage and/or grade. For all patients
the percentages of single
multiple tumors
stage Ta
T1
grade 1
2 and 3 tumors were 23.23%
42.59%
6.25%
34.78%
17.05%
37.25% and 62.07%
respectively. No difference in tumor stages
grades
and numbers was found between observation and control groups (P0.05). The recurrence rate for observation group was significantly lower than control group (14.15% vs 36.72%
P0.01). Furthermore
recurrence rates for single tumors
stage Ta or low grade tumors was significantly lower than multiple tumors
stage T1 or high grade tumors
respectively (P0.01). Conclusion There are various high risks associated with recurrences of STCC patients after TUR
such as those with high grades
at advanced stages
multiple lesions and non-papillary growth patterns of tumors
as well as invisible satellite lesions
omissions of small tumors due to anthropic factors
replantation of residual tumor fragments
failure of irrigative chemotherapy
etc. A standardized thoroughly resection of the primary tumor
combined with normalized vesical irrigative chemotherapy using chemicals and immunoreagents
including chemotherapy instantly after TUR
will promote the clinical outcome and decrease the recurrence rate.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621